THE ECONOMIC IMPACT OF SWITCHING TO HERCEPTIN (TRASTUZUMAB) BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A UK PAYER PERSPECTIVE

被引：0
|
作者：
Brown, D. [1 ]
Bozkaya, D. [1 ]
机构：
[1] Xcenda LLC, Palm Harbor, FL USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.157
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN74
引用
收藏
页码：A425 / A425
页数：1
相关论文
共 50 条
  • [1] THE ECONOMIC IMPACT OF SWITCHING TO TRASTUZUMAB BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A CHINESE PAYER PERSPECTIVE
    Liu, S.
    Bozkaya, D.
    Brown, D.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [2] Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
    Hortobagyi, GN
    SEMINARS IN ONCOLOGY, 2001, 28 (06) : 43 - 47
  • [3] Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer
    Suter, TM
    Cook-Bruns, N
    Barton, C
    BREAST, 2004, 13 (03): : 173 - 183
  • [4] Impact of innovative and expensive therapies in the treatment of metastatic breast cancer (MBC): Focus on trastuzumab (herceptin(H))
    Miadi-Fargier, H
    Trillet-Lenoir, V
    Ganne, C
    Couray-Targe, S
    Colin, C
    VALUE IN HEALTH, 2002, 5 (06) : 541 - 541
  • [5] Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN®) to biosimilar trastuzumab (Trastuzumab-NK) in the treatment of HER2-positive breast cancer
    Abe, Tomoya
    Sagara, Atsunobu
    Okada, Daichi
    Matsuzaka, Kazumasa
    MOLECULAR AND CLINICAL ONCOLOGY, 2023, 18 (05)
  • [6] Herceptin in the treatment of metastatic breast cancer
    Konecny, G
    Untch, M
    Pegram, M
    GYNAKOLOGE, 1999, 32 (08): : 624 - 631
  • [7] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    August Cesarec
    Robert Likić
    Applied Health Economics and Health Policy, 2017, 15 : 277 - 286
  • [8] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    Cesarec, August
    Likic, Robert
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 277 - 286
  • [9] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Xiaoying Chen
    Cheryl Li
    Reginald Ewesuedo
    Donghua Yin
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 83 - 92
  • [10] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Chen, Xiaoying
    Li, Cheryl
    Ewesuedo, Reginald
    Yin, Donghua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 83 - 92
12345